Harmine reduces ROS-mediated hepatotoxicity in a cisplatin mouse model
Research in Pharmaceutical Sciences · 2026-07 · 21 (4) · 452-465
DOI: 10.4103/rps.rps_194_25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Research in Pharmaceutical Sciences, online erschienen am 27.07.2026. Verfasst von Cyrus Jalili und 7 weiteren Autor:innen. Beteiligte Einrichtung: Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background and purpose: Cisplatin, a widely used anticancer agent, has adverse effects on normal tissues during cancer treatment. This study aimed to investigate the use of harmine, a plant β-carboline alkaloid, against pathways associated with ROS-induced apoptosis in the livers of mice administered with cisplatin. Experimental approach: Twenty-four male Balb/c mice were randomly assigned to four groups (n = 6): (1) control group received daily intraperitoneal injections of saline for four days, (2) harmine group (15 mg/kg, intraperitoneally, daily for 4 days), (3) cisplatin group (5.5 mg/kg, intraperitoneally, one injection), and (4) cisplatin + harmine co-administration group. After sacrificing the animals under deep anesthesia, blood and liver tissue samples were collected for biochemical and molecular experiments. Findings/Results: Cisplatin significantly elevated histopathological criteria (both qualitative and quantitative), levels of enzyme activity, malondialdehyde, nitric oxide, ROS, and apoptosis, and decreased glutathione, superoxide dismutase, and total antioxidant capacity. However, these factors were improved in the co-administration group compared to the cisplatin group. Furthermore, cisplatin treatment significantly upregulated caspase-8, BAX, p53, caspase-3, TNF-α , and NF-κB gene expression, while downregulating BCL-2 . Co-administration with harmine led to significant changes in gene expression relative to the cisplatin group. Cisplatin notably increased protein levels of caspase-8, BAX, and TNF-α, but these levels were significantly reduced in the co-treatment group. Conclusion and implications: Harmine effectively ameliorates cisplatin-induced hepatitis by suppressing ROS production, thereby reducing intrinsic, extrinsic, and inflammation-induced apoptosis. These findings suggest that the antioxidant and anti-inflammatory properties of Harmine play a key role in its hepatoprotective actions.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Department of Nanobiotechnology, Faculty of Strategic Sciences and Technologies, Razi University, Kermanshah, Iran.
- Student Research Committee, Kermanshah University of Medical Sciences, Kermanshah, Iran.
- Medicinal Plant Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
- Department of Biochemistry and Molecular Biology, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
- Stem Cells and Transgenic Technology Research Center, Shahid Chamran University of Ahvaz, Ahvaz, Iran.
Zitieren
APA
Jalili, C., Akhshi, N., Mohebi, H., Zamir-Nasta, T., Tabandeh, M. R., Esmaeli, M., Ravankhah, S., & Ghanbari, A. (2026). Harmine reduces ROS-mediated hepatotoxicity in a cisplatin mouse model. Research in Pharmaceutical Sciences, 21(4), 452-465. https://doi.org/10.4103/rps.rps_194_25
Vancouver
Jalili C, Akhshi N, Mohebi H, Zamir-Nasta T, Tabandeh MR, Esmaeli M, et al. Harmine reduces ROS-mediated hepatotoxicity in a cisplatin mouse model. Research in Pharmaceutical Sciences. 2026;21(4):452-465. doi:10.4103/rps.rps_194_25
BibTeX
@article{Jalili2026,
author = {Jalili, Cyrus and Akhshi, Nasim and Mohebi, Hossein and Zamir-Nasta, Touraj and Tabandeh, Mohammad Reza and Esmaeli, Mojtaba and Ravankhah, Saeed and Ghanbari, Ali},
title = {Harmine reduces ROS-mediated hepatotoxicity in a cisplatin mouse model},
journal = {Research in Pharmaceutical Sciences},
year = {2026},
volume = {21},
number = {4},
pages = {452--465},
doi = {10.4103/rps.rps_194_25}
}
EUVIMED